These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16321824)

  • 21. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
    Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
    Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).
    Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
    Ann Oncol; 2008 Jun; 19(6):1172-9. PubMed ID: 18272909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
    Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
    Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.
    Wang S; Hong S; Wezeman M; Qian J; Yang J; Yi Q
    Front Biosci; 2007 May; 12():3566-75. PubMed ID: 17485322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
    Cohen S; Haimovich J; Hollander N
    J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
    Yi Q; Desikan R; Barlogie B; Munshi N
    Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
    Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL
    Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
    Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
    Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel immunotherapies.
    Yi Q
    Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
    Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
    Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
    J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
    Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
    Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
    J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells in clinical trials for multiple myeloma.
    Reichardt VL; Brossart P
    Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv
    Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract]   [Full Text] [Related]  

  • 38. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
    Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
    Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
    Pyzer AR; Avigan DE; Rosenblatt J
    Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
    Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
    Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.